Tumor radiosensitization based on the use of inhibitors of the mevalonate pathway of cholesterol synthesis.
Miller
A C
AC
Department of Radiation Biochemistry, AFRRI, Bethesda, MD 20889, USA.
Samid
D
D
D000230:Adenocarcinoma; D001932:Brain Neoplasms; D001943:Breast Neoplasms; D002470:Cell Survival / Q000187:drug effects* / Q000528:radiation effects*; D002784:Cholesterol / Q000096:biosynthesis*; D003037:Cobalt Radioisotopes; D003110:Colonic Neoplasms; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000096:biosynthesis; D053138:Cyclohexenes; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005354:Fibrosarcoma; D005720:Gamma Rays; D011905:Genes, ras / Q000187:drug effects / Q000528:radiation effects; D005909:Glioblastoma; D006801:Humans; D000077222:Limonene; D008175:Lung Neoplasms; D008297:Male; D008798:Mevalonic Acid / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011471:Prostatic Neoplasms; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*; D013729:Terpenes / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
C493956:CDKN1A protein, human; D003037:Cobalt Radioisotopes; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D053138:Cyclohexenes; D011838:Radiation-Sensitizing Agents; D013729:Terpenes; D002784:Cholesterol; D000077222:Limonene; D008798:Mevalonic Acid